 "Strides Arcolab gains on USFDA OKs oral dosage facility at Bangalore")
Strides Arcolab is trading higher by 4% at Rs 933 on BSE in otherwise weak market after the drug maker said that its oral dosage facility (KRS Gardens) at Bangalore has been found acceptable by the United States Food and Drug Administration (US FDA).
The oral dosage facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets. The manufacturing plant supports important current and future submissions for the US Market, Strides Arcolab said in a statement.
The inspection was carried out in August 2014, it added.
The stock opened at Rs 905 and hit a high of Rs 942 on BSE. The trading volumes on the counter almost doubled with a combined 680,449 shares changed hands till 1516 hours on BSE and NSE.
The oral dosage facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets. The manufacturing plant supports important current and future submissions for the US Market, Strides Arcolab said in a statement.
The inspection was carried out in August 2014, it added.
The stock opened at Rs 905 and hit a high of Rs 942 on BSE. The trading volumes on the counter almost doubled with a combined 680,449 shares changed hands till 1516 hours on BSE and NSE.